news archive genetic news - February 6, 2006

February 6, 2006

your information resource in human molecular genetics

-	Dosing convenience mandates the pipeline of glucagon-like peptide-1 (GLP-1) analogs for type 2 diabetes Twice-daily injection is the benchmark set by exenatide, the first GLP-1 analog launched in the US by Lilly in June 2005 and half-year sales of US$ 74.6 mln, which now faces competition by GLP-1 analog treatment modalities with less frequent dosing.
-	*Association between schizophrenia and the DISC1* gene** Polymorphisms increase risk of schizophrenia in Scottish population sample